LLY

905.59

-0.41%↓

JNJ

239.87

+0.08%↑

ABBV

208.44

+0.12%↑

NVS

150.89

-0.13%↓

MRK

119.75

+0.73%↑

LLY

905.59

-0.41%↓

JNJ

239.87

+0.08%↑

ABBV

208.44

+0.12%↑

NVS

150.89

-0.13%↓

MRK

119.75

+0.73%↑

LLY

905.59

-0.41%↓

JNJ

239.87

+0.08%↑

ABBV

208.44

+0.12%↑

NVS

150.89

-0.13%↓

MRK

119.75

+0.73%↑

LLY

905.59

-0.41%↓

JNJ

239.87

+0.08%↑

ABBV

208.44

+0.12%↑

NVS

150.89

-0.13%↓

MRK

119.75

+0.73%↑

LLY

905.59

-0.41%↓

JNJ

239.87

+0.08%↑

ABBV

208.44

+0.12%↑

NVS

150.89

-0.13%↓

MRK

119.75

+0.73%↑

Inicio・Lista de Acciones・Avita Therapeutics Inc

Avita Therapeutics Inc

Cerrado

3.95 3.4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.82

Máximo

4.04

Métricas clave
By Trading Economics
Ingresos	1.6M -12M
Ventas	554K 18M
BPA	-0.536
Margen de beneficios	-65.968
Empleados	226
EBITDA	1.6M -9.7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+64.84% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-2.5M 121M
Apertura anterior	0.55
Cierre anterior	3.95

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.83 / 9.77 Soporte y Resistencia

Avita Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 mar 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Infosys Agrees to Acquire Stratus

25 mar 2026, 23:58 UTC

Ganancias

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mar 2026, 23:58 UTC

Ganancias

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mar 2026, 23:57 UTC

Ganancias

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mar 2026, 23:57 UTC

Ganancias

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mar 2026, 23:56 UTC

Ganancias

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mar 2026, 23:56 UTC

Ganancias

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mar 2026, 23:41 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mar 2026, 23:41 UTC

Ganancias

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mar 2026, 23:34 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Declines on Possible Technical Correction -- Market Talk

25 mar 2026, 22:08 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 mar 2026, 22:08 UTC

Charlas de Mercado

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mar 2026, 21:58 UTC

Charlas de Mercado

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mar 2026, 21:37 UTC

Charlas de Mercado

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mar 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mar 2026, 21:13 UTC

Adquisiciones, fusiones, absorciones

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mar 2026, 21:12 UTC

Adquisiciones, fusiones, absorciones

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

25 mar 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

25 mar 2026, 20:33 UTC

Adquisiciones, fusiones, absorciones

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mar 2026, 20:31 UTC

Ganancias

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Comparación entre iguales

Cambio de precio

Avita Therapeutics Inc previsión

Precio Objetivo

By TipRanks

64.84% repunte

Estimación a 12 Meses

Media 6.33 USD 64.84%

Máximo 10 USD

Mínimo 3.5 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avita Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Avita Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.83 / 9.77Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.